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ABSTRACT
Partial loss of large ribosomal subunit protein 24 (RPL24) function is known to 
protect mice against Akt or Myc-driven cancers, in part via translational inhibition 
of a subset of cap(eIF4E)-dependently translated mRNAs. The role of RPL24 in 
human malignancies is unknown. By analyzing a public dataset of matched human 
breast cancers and normal mammary tissue, we found that breast cancers express 
significantly more RPL24 than matched normal breast samples. Depletion of RPL24 
in breast cancer cells by >70% reduced cell viability by 80% and decreased protein 
expression of the eIF4E-dependently translated proteins cyclin D1 (75%), survivin 
(46%) and NBS1 (30%) without altering GAPDH or beta-tubulin levels. RPL24 
knockdown also reduced 80S subunit levels relative to 40S and 60S levels. These 
effects on expression of eIF4E-dependent proteins and ribosome assembly were 
mimicked by 2-24 h treatment with the pan-HDACi, trichostatin A (TSA), which 
induced acetylation of 15 different polysome-associated proteins including RPL24. 
Furthermore, HDAC6-selective inhibition or HDAC6 knockdown induced ribosomal 
protein acetylation. Via mass spectrometry, we found that 60S-associated, but not, 
polysome-associated, RPL24 undergoes HDACi-induced acetylation on K27. Thus, 
RPL24 K27 acetylation may play a role in ribosome assembly. These findings point 
toward a novel acetylation-dependent polysome assembly mechanism regulating 
tumorigenesis. 
INTRODUCTION
Control of protein synthesis is commonly 
dysregulated in cancer, most frequently by mutational 
activation of the phosphoinositide 3-kinase, protein kinase 
B/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) 
pathway. The PI3K/Akt/mTOR pathway promotes cell 
survival and growth, by inducing the phosphorylation 
of the small (40S) ribosomal subunit protein S6 (RPS6) 
and the eukaryotic initiation factor 4e binding protein 1 
(4eBP1). These events stimulate polysome (polyribosome) 
assembly and increase cap-dependent (eIF4E-dependent) 
translation of tumorigenic mRNAs [1-4]. 
Recent studies indicate that other pathways, in 
addition to the PI3K/Akt/mTOR pathway, can cause 
translational dysregulation in cancer. For example, 
the rRNA methyltransferase WBSCR22 is involved 
in the biogenesis of the 40S ribosomal subunit and is 
overexpressed in invasive breast cancer [5]. The large 
ribosomal subunit protein 24 (RPL24) is another translation 
factor previously linked to tumorigenesis. Homozygous 
RPL24 deficiency is lethal in mice. In contrast, RPL24 
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haploinsufficient mice are viable with specific eye, 
skeletal, and coat pigment defects [6]. Interestingly, these 
RPL24 haploinsufficient mice show greater survival 
from Akt-induced lymphomagenesis. This protection is 
associated with an overall decrease in thymocyte protein 
synthesis [7]. Likewise, RPL24 haploinsufficient mice 
are protected from Myc-driven tumorigenesis. This same 
study demonstrated that Myc-induced tumorigenesis 
arises by increased cap-dependent translation that is also 
prevented by RPL24 haploinsufficiency [8]. In studies 
of human lung adenocarcinoma cells depleted of RPL24 
by RNA interference, and in RPL24 haploinsufficient 
mouse embryonic fibroblasts (MEFs), RPL24 reduction is 
associated with increased p53 expression [9], suggesting 
that the prevention of tumorigenesis by reduced RPL24 
may also depend on a p53-dependent checkpoint 
mechanism. 
A full understanding of the role of RPL24 in 
tumorigenesis requires mechanistic elucidation of how 
RPL24 interacts with other ribosomal proteins and 
translation factors. RPL24 is one of the later proteins to 
be incorporated into the large ribosomal subunit, where it 
then regulates the joining of the 60S subunit to the small 
40S subunit [10-12]. Crystallography of the Tetrahymena 
thermophilis 60S ribosomal subunit and cryo-electron 
microscopy reconstruction of the Saccharomyces 
cerevisiae 60S indicate that RPL24 resides on a surface of 
the 60S ribosomal subunit close to where the eukaryotic 
initiation factor 6 (eIF6) contacts the 60S [13-15]. The 
anti-assembly factor, eIF6, binds to the pre-60S ribosomal 
subunit and prevents premature association of 60S with the 
40S subunit. Following 60S maturation, eIF6 is released, 
allowing for the joining of the 40S sand 60S subunits to 
form the 80S ribosome and further assembly of polysomes 
[16-20]. 
Given the known role of RPL24 in murine 
tumorigenesis and therapeutic interest in eIF4E-driven 
human breast cancers [21], we asked if RPL24 expression 
is also altered during human breast tumorigenesis, and 
observed that most human breast cancers overexpress 
RPL24 relative to normal breast tissue. We then 
demonstrated that RPL24 depletion in breast cancer 
cells reduces their growth and viability in association 
with selectively impaired expression of cap-dependent 
proteins needed for survival and proliferation, while 
also inhibiting 80S ribosome and polysome assembly by 
preventing eIF6 release from the 60S subunit. We also 
showed that 2-24 h treatment with a pan-inhibitor of 
class I and II histone deacetylases, trichostatin-A (TSA), 
mimics the above effects of RPL24 depletion, inducing 
60S subunit-associated acetylation of RPL24 at K27. TSA 
also induced acetylation of polysomal RPL24 at K93 and 
14 other ribosomal proteins. Comparison of pan-, class-, 
and isotype-selective HDACi’s suggested that HDAC6 
controls total acetylation levels of ribosomal proteins, a 
conclusion supported by HDAC6 knockdown studies.
RESULTS
RPL24 expression is transcriptionally upregulated 
during human breast tumorigenesis
Since RPL24 haploinsufficiency impairs the 
formation of both Akt-driven and Myc-driven murine 
malignancies [7-9], we looked for evidence that RPL24 
upregulation may contribute to human tumorigenesis as 
well. To that end, we compared microarrayed samples 
of human cancers paired with their normal organ tissue 
Figure 1: RPL24 expression is transcriptionally upregulated during human breast tumorigenesis. RPL24 expression 
levels were analyzed from the dataset presented in [22]. (a) Box plot of RPL24 expression levels in patient-matched breast carcinoma and 
normal breast tissues. Lines connect paired data from each patient; and line color reflects relative levels of RPL24 in each paired sample 
(red: tumor > normal; green: normal > tumor). (b) Differences in RPL24 expression levels between each breast carcinoma and normal 
breast sample pair. The mean of the differences + SD are shown in red. P-value was obtained using a paired t-test.
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samples. Using a public dataset of RNA profiles reported 
from 43 pairs of breast cancer and normal breast samples 
[32], we determined that approximately two-thirds of the 
breast cancers showed increased RPL24 transcript levels 
relative to their matched normal breast sample (Figure 1a). 
The entire group of tumor samples exhibited a significant 
20% mean overall increase in RPL24 expression levels 
(p = 0.001), indicating that transcriptional upregulation of 
RPL24 commonly occurs in human breast tumorigenesis 
(Figure 1b).
RPL24 knockdown reduces breast cancer cell 
viability while inhibiting cap (eIF4eE)-dependent 
expression of proliferation, survival and genome 
stability proteins
Studies of RPL24 haploinsufficient mice protected 
from Myc-driven tumorigenesis revealed that dysregulated 
cap-dependent protein synthesis not only induces tumor 
formation but also results in cell cycle dysregulation and 
genomic instability [8]. Since the translation-dependent 
checkpoint mechanism remains undefined, we evaluated 
the impact of RPL24 depletion in a model human breast 
cancer cell line, SKBR3, sensitive to eIF4E-regulated and 
cap-dependent translation inhibition [33]. Two different 
RPL24-directed shRNA-expressing lentiviruses were used 
to decrease RPL24 protein expression by approximately 
70% (Figure 2a). This resulted in a 5-fold (80%) reduction 
in SKBR3 cell viability measured after 4 days in culture 
(Figure 2b). Associated with RPL24 depletion and growth 
inhibition was a marked reduction in the expression 
of three different eIF4E-regulated and cap-dependent 
transcripts necessary for cell proliferation (75% reduction 
in cyclin D1), survival (46% reduction in survivin), and 
DNA repair and integrity (30% reduction in NBS1). 
Protein levels of two housekeeping genes not regulated 
by eIF4E [21, 33-35], GAPDH and β-tubulin, were not 
affected by RPL24 depletion (Figure 2a).
RPL24 knockdown reduces 80S and polysome 
assembly while increasing 60S retention of eIF6 
Since RPL24 depletion decreased the levels of 
three cap-dependently translated proteins, we next 
evaluated the impact of RPL24 knockdown on overall 
ribosome and polysome formation in these cells. We 
used polysome profiling, which utilizes continuous 
sucrose gradient fractionation to separate free 40S and 
60S ribosomal subunits, 80S ribosomes, and polysomes 
(two or more ribosomes on one mRNA). The ratio of both 
80S ribosomes and polysome peaks relative to free 40S 
and 60S ribosomal subunits was significantly reduced 
Figure 2: RPL24 knockdown reduces breast cancer cell viability while inhibiting cap (eIF4E)-dependent expression 
of proliferation, survival and genome stability proteins. SKBR3 cells were infected with lentiviruses expressing a GFP control or 
RPL24-targeting shRNA. After one week of puromycin selection, cells were plated in 96-well plates for viability assays and lysates were 
taken in parallel for western blots. (a) Western blots were performed on lysates from an equal number of cells using antibodies toward the 
indicated proteins. Ratios of protein expression normalized to beta-tubulin levels were obtained using ImageJ software. (b) Viability assay 
readings were taken three hours after plating (day 0) and four days after plating (day 4). The day 4 results were normalized for plating 
efficiency using the day 0 values. Error bars represent three replicate samples. 
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in SKBR3 cells following efficient RPL24 knockdown 
(Figure 3a,b). This observed increase in 40S and 60S 
subunits relative to 80S ribosomes implies a defect in 
40S-60S joining induced by the RPL24 knockdown. 
Since eIF6 bound to the pre-60S subunit prevents 
joining of the 40S and 60S subunits [16-20] and occurs 
adjacent to RPL24 on 60S [13] (Figure 3c), we performed 
immunoblotting on all 60S-containing polysome fractions 
to evaluate the impact of RPL24 knockdown on eIF6 
retention. Probing fractions corresponding to the area 
of the polysome profile near the 60S peak for Rack1, an 
obligatory 40S component, and RPL4, an obligatory 60S 
component, confirmed that these fractions do, in fact, 
encompass the 60 subunit. As expected, RPL24 levels 
were drastically decreased in SKBR3 cells expressing 
RPL24 shRNA. Associated with RPL24 knockdown was 
a striking increase in 60S-associated eIF6 (Figure 3d). To 
rule out the possibility that the observed 60S retention of 
eIF6 might be a false-positive or non-specific artifact of 
lentiviral expressed RPL24 shRNA, we overexpressed a 
functionally deficient truncation mutant of RPL24 that 
eliminates the last 17 amino acids. Polysome profiling 
of 293T cells expressing intact versus truncated RPL24 
protein confirmed that truncated RPL24 can induce 60S 
retention of eIF6 (Figure S1).
Ribosomal protein acetylation is induced by pan-
HDACi and HDAC6-selective inhibitors
Previous studies have shown that pan-inhibitors 
of class I and II histone deacetylases (pan-HDACi), like 
TSA, can rapidly destabilize a number of oncogenic 
transcripts including HER2 in a cycloheximide-dependent 
manner (Figure S2, [25, 36]). Since cycloheximide 
inhibits polysome formation, these results suggested that 
polysomes are possibly involved in HER2 mRNA decay. 
Thus, SKBR3 cells were treated with TSA to evaluate 
polysome protein acetylation and determine if, similar to 
RPL24 depletion, HDACi can affect ribosome assembly 
dynamics. To detect early (2 h) ribosome or polysome 
acetylation following HDACi treatment (1 µM TSA), 
SKBR3 polysomes were isolated using a discontinuous 
sucrose gradient as previously described [28]. Western 
blots using an antibody against acetylated lysine 
residues showed several TSA-induced bands, including 
a prominent TSA-induced acetyl-lysine protein band co-
migrating with RPL24 (Figure 4a, indicated by arrow), 
while total RPL24 levels were not altered by TSA. Mass 
spectrometry studies indicate that 15 ribosomal proteins, 
11 large subunit proteins (RPL24 included) and 4 small 
subunit proteins, underwent at least a two-fold induction 
in acetylation following 2h or 6h TSA treatment (1 µM) 
(Figure 4b, Figure S3a-q). 
Like TSA, the HDAC6 (class IIb)-selective 
Figure 3: RPL24 knockdown reduces 80S and polysome assembly while increasing 60S retention of eIF6. (a,b,d) SKBR3 
cells were infected with lentiviruses expressing a GFP control or RPL24-targeting shRNA for three days. (a) Western blots using the 
indicated antibodies were performed on total cell lysates to assess knockdown efficiency. (b) Lysates were applied to a continuous sucrose 
gradient (10-50%) and ultracentrifugation followed by fractionation was performed to separate ribosomal subunits and polysomes. (c) 
Pymol software was used to visualize the location of RPL24 (blue) relative to eIF6 (green) on the previously published structure of the 60S 
subunit in complex with eIF6 [13]. (d) Western blots using the indicated antibodies were performed on fractions from the 60S peaks using 
the indicated antibodies. 
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inhibitors, Tubacin and ACY-775, as well as HDAC6 
siRNA, all induce tubulin acetylation as expected as 
well as ribosomal protein acetylation, including the band 
that co-migrates with RPL24 (Figure 4c,d, indicated by 
arrows). Although the class I-specific HDACi, Entinostat, 
induces histone H2B acetylation without acetylating 
tubulin, it does not alter ribosomal protein acetylation 
even at a dose of 20 µM (Figure 4c). Thus, the tubulin-
acetylating effects of pan-HDACi, known to be mediated 
by inhibition or knockdown of HDAC6, correspond to 
the observed ribosome and RPL24 acetylation responses 
induced by TSA.
Like RPL24 knockdown, HDACi reduces 80S 
assembly while increasing 60S retention of 
eIF6 and reduces expression of cap (eIF4E)-
dependently translated proteins
Using continuous sucrose gradient fractionation 
of SKBR3 polysomes, 2 h culture treatment with TSA 
reduced 80S and polysome assembly (Figure 5a) while 
Figure 4: Ribosomal protein acetylation is induced by pan-HDACi and HDAC6-selective inhibitors. (a-c) SKBR3 cells 
were treated with the indicated drugs for the indicated period of time. (d) SKBR3 cells were transfected with the indicated siRNAs and 
allowed to incubate for 72 hours. (a, c, d). The indicated western blots were performed in ribopellets, total cytoplasmic lysates, or nuclear 
extracts. (b) Mass spectrometry was performed on ribopellets as described in materials and methods and in Figure 6. The fold change in 
acetylated peptide to total peptide caused by TSA treatment is plotted. Only proteins that underwent at least a two-fold induction upon TSA 
treatment are shown. Error bars represent the standard error of the mean for three biological replicates.
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increasing 60S retention of eIF6 without reducing 60S 
RPL24 levels (Figure 5b). This result is comparable 
to that produced by RPL24 knockdown (Figure 3) or 
truncation (Figure S1). Furthermore, similar to RPL24 
knockdown, 24 h TSA treatment reduced the expression 
of the cap(eIF4e)-dependently translated proteins cyclin 
D1, survivin, and NBS1 relative to the housekeeping 
proteins GAPDH and β-tubulin (Figure 5c). Shorter (8 h) 
TSA treatment reduced cyclin D1 levels but not survivin 
or NBS1 levels. The more rapid reduction of cyclin D1 
levels was likely caused by the known effects of TSA on 
cyclin D1 transcription and transcript stability in addition 
to its effects on translation [37]. 
HDACi enhances lysine (K27) acetylation on 60S 
RPL24 
Mass spectrometry studies were performed to 
identify sites of lysine (K) acetylation within RPL24 
induced by HDACi. Continuous and discontinuous 
sucrose gradient fractionations were performed to 
isolate 60S subunits and total polysomes respectively. 
Polyacrylamide gel electrophoresis was then performed on 
60S and polysome samples and RPL24-containing bands 
were excised, trypsin digested, and subjected to mass 
spectrometry (LC-MS/MS) (Figure 6a). Among several 
detected acetylated RPL24 peptides, two were increased 
by TSA treatment; TDGKacVFQFLNAK (acetyl-K27) 
and AITGASLADIM*AKacR (acetyl-K93), where the 
internal lysines in both peptides are N-acetylated (Kac). As 
the MS experiments of the 60S polysome were performed 
after in-gel digestion the methionine residue of the second 
peptide was predominantly oxidized (M*=M+16), as 
commonly observed during SDS PAGE processing. 
In independent, in-solution digestion experiments, we 
also identified the corresponding non-oxidized form 
of acetylated peptide AITGASLADIMAKacR with 
correlating MS/MS fragmentation pattern. Representative 
spectra are shown for TDGKac VFQFLNAK (acetyl-K27) 
and AITGASLADIM*AKacR (acetyl-K93)) (Figure 
S4a,b). In 3 biological replicate experiments, the amount 
of K27-acetylated RPL24, normalized to total protein 
concentration within the 60S subunit, was increased at 
least 2-fold within 2 h of TSA treatment. However, there 
was no significant induction of RPL24 K27 acetylation 
found within polysomes (not containing 60S subunits) 
(Figure 6b). In contrast, RPL24 K93 acetylation within 
the 60S subunits was not significantly changed by TSA 
treatment, yet K93 acetylation was induced 2.5-fold within 
RPL24 associated with polysomes (Figure 6c). Given the 
proximity of the T. thermophilia RPL24 K26 site (that 
resides in a homologous region to human K27) to eIF6 
(Figure 7a), these findings implicate involvement of the 
TSA induced acetylation of RPL24 at K27 in preventing 
40S-60S subunit joining and 60S retention of eIF6. 
DISCUSSION 
Consistent with the role of RPL24 in protecting 
Figure 5: Like RPL24 knockdown, HDACi reduces 
80S assembly while increasing 60S retention of eIF6 
and reduces expression of cap (eIF4)-dependently 
translated proteins. (a,b) SKBR3 cells were treated with TSA 
(1 μM, 2 h). (a) Polysome profiles were carried out as previously 
described. (b) Western blots using the indicated antibodies were 
performed in fractions representing the 60S subunits. (c) SKBR3 
cells were treated with TSA for the indicated doses and times, 
and proteins were identified by western blotting as indicated. 
Ratios of protein expression normalized to beta-tubulin levels 
were obtained using ImageJ software.
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against Akt-driven and Myc-driven murine tumorigenesis 
[7, 8], the present study provides new evidence that, not 
only is elevated RPL24 expression common in human 
breast tumors, but depletion or structural alteration of 
RPL24 can significantly impair human breast cancer 
cell viability (Figure 1,2). Our results indicate that 
this could occur through a reduction in cap(eIF4E)-
dependent translation of proteins essential for cancer cell 
proliferation (e.g. cyclin D1), survival (e.g. survivin) and 
genome repair (e.g. NBS1) (Figure 2). Our findings also 
indicate that the mechanism of action by which RPL24 
deficiency reduces expression of these proteins essential 
for cancer cell viability involves failure of 40S and 60S 
ribosomal subunit joining into functional 80S ribosomes 
by retention of eIF6 on 60S subunits (Figure 3). 
Although RPL24 is an essential ribosomal protein, 
partial (up to 70%) depletion of RPL24 does not reduce 
the expression of all proteins but preferentially inhibits 
expression of eIF4E-regulated and cap-dependently 
translated proteins. In particular, the translation of 
housekeeping genes like GAPDH and β-tubulin remained 
unaffected when assessed by protein levels normalized 
to total cell number (Figure 2). In contrast, cyclin D1, 
survivin, and NBS1 are among several well-known 
growth, survival and tumorigenic transcripts with highly 
structured 5’ untranslated regions (UTRs) whose cap-
dependent ribosomal translation is tightly regulated by 
eIF4E; and their synthesis was reduced by as much as 75% 
following partial depletion of RPL24. These results raise 
the possibility that RPL24 depletion changes ribosome 
structure or recruitment factors in a manner that causes 
ribosomes to be recruited to cap-dependently translated 
mRNAs less efficiently. 
As demonstrated in this study and schematically 
illustrated in Figure 7b, treatment of breast cancer cells 
with a pan-HDACi like TSA induces recruitment of eIF6 
Figure 6: HDACi enhances lysine (K27) acetylation 
on 60S, but not polysomal, RPL24. (a) Schematic of 
mass-spectrometry-based techniques to analyze ribosomal 
protein acetylation. SKBR3 cells were treated with TSA (1 
μM, 2 h or 6 h). To isolate 60S subunits, polysome profiles 
were performed and 60S fractions were TCA precipitated. 
Concentrated 60S samples were resolved on 4-12% bis-tris gels 
and RPL24-containing bands were excised and trypsin digested. 
In parallel, polysomes were isolated using a discontinuous 
sucrose gradient as described. Trypsin digestions and acetyl 
lysine immunoprecipitations were subsequently carried out. 
Mass spectrometry was performed on 60S-associated RPL24-
containing gel bands or polysome-containing acetyl-lysine 
immunoprecipitations as described in the methods section.  (b,c) 
On 60S-associated and polysome-associated RPL24, the fold 
induction caused by TSA (1 µM, 2 h) of K27 (b) or K93 (c)-
acetylated peptide (normalized to total protein concentration) 
was plotted. Error bars represent the standard error of the mean 
for three biological replicates. Note: the data for K93 acetylation 
of RPL24 K93 is also shown in Figure 4b.
Figure 7: Schematic for modulation of ribosome 
assembly by RPL24 acetylation. (a) A magnified portion of 
the RPL24 (blue)-eIF6 (green) interface, visualized with Pymol 
software, from previous x-ray crystallography data [13], is 
shown (zoomed out view shown in Figure 3c) . T. thermophilia 
RPL24 residues are labelled and K26, which resides in a region 
of RPL24 homologous to where human K27 resides, is circled. 
(b) eIF6 binds to the pre-60S near RPL24 to prevent premature 
association of the 40S and 60S ribosomal subunits; eIF6 is then 
released from the mature 60S, allowing it to join with the 40S to 
form the 80S ribosome. Our model indicates that either RPL24 
depletion or TSA (HDACi)-induced RPL24 acetylation on K27 
prevents eIF6 release and 80S formation.
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to 60S subunits along with acetylation of RPL24 at K27, 
likely impairing 40S-60S joining. These phenotypes 
mimic RPL24 knockdown (Figure 3, Figure 5). 
Consistent with this finding, the crystal structure of the T. 
thermophilia 60S subunit [13] reveals that RPL24 K26, 
which closely aligns with human RPL24 K27, is adjacent 
to eIF6 (Figure 3c, 7a). While we detected multiple sites 
of acetylation on RPL24, only K27 acetylation was 
induced by HDACi in association with the 60S subunit. 
Similar to RPL24 depletion, 24 h of HDACi treatment 
reduced the expression of cyclin D1, survivin, and 
NBS1 relative to GAPDH and β-tubulin (Figure 5c), a 
possible secondary consequence of the 60S acetylation 
and ribosome assembly failure noted as early as 2 h after 
TSA treatment. These timing differences in responses to 
the same TSA treatment suggest that although ribosome 
assembly is inhibited rapidly, it takes hours for the effects 
of such a functional impairment in ribosome assembly to 
manifest as a significant reduction in the pools of proteins 
synthesized by cap-dependent translation. 
Our findings point toward the existence of an as 
yet unrecognized endogenous and acetylation-dependent 
mechanism that regulates both polysome assembly and 
cap-dependent protein translation. Including RPL24, 
we identified fifteen ribosomal proteins that undergo 
acetylation induction two-fold or more as a rapid 
consequence of HDACi treatment. These proteins are 
also potential contributors to this acetylation-dependent 
control of ribosome assembly. Like pan-HDACi treatment, 
enzymatic inhibition or knockdown of cytoplasmic 
HDAC6 appears to be sufficient to induce polysomal 
protein acetylation, in contrast to a class I-selective 
HDACi like Entinostat which has no such affect (Figure 
4). Since only 2-6 h treatment with an HDAC6-selective 
inhibitor induces near maximum levels of ribosome 
protein acetylation, this posttranslational structural change 
is likely due to a direct cytoplasmic HDAC effect on 
ribosomal proteins rather than any indirect effect mediated 
by HDAC regulated nuclear gene expression. 
In view of the current lack of any drug-like agent 
that can specifically target RPL24, our study also points 
toward RPL24 as a previously unrecognized subcellular 
target potentially contributing to the known anticancer 
activity of two approved cancer therapeutics, vorinostat 
and romidepsin, that are HDACi’s like TSA, not to 
mention contributing to the anticancer mechanisms of 
investigational HDAC6-selective inhibitors like ACY-775. 
The fact that homozygous loss of RPL24 is embryonic 
lethal [6] might cause concern about developing a target-
specific anti-RPL24 cancer therapeutic. However, it is 
important to recall that the homozygous deletion of many 
well-established breast cancer drug targets, such as human 
epidermal growth factor receptor (HER2), mTOR, and 
the catalytic domain of PI3K, are also embryonic lethal 
[38-41], yet this fact did not preclude or even delay the 
successful clinical development of therapeutics selective 
for these targets. The fact that RPL24 haploinsufficiency 
is compatible with normal murine lifespan is additionally 
reassuring from the standpoint of developing an anti-
RPL24 therapeutic, and points to the established fact that 
all approved anticancer agents rely on in vivo definition 
of an optimal therapeutic window, whereby anticancer 
efficacy vastly exceeds host toxicity. Given that RPL24 
haploinsufficiency protects mice from Akt- and Myc-
driven tumorigenesis [7, 8], it is interesting to note that 
at least 40% of basal-like breast cancers overexpress Akt 
or Myc [42], indicating that anti-RPL24 therapeutics 
could be effective against basal-like and other clinically 
aggressive subsets of human breast cancer. 
METHODS
Analysis of RPL24 expression in patient-matched 
breast carcinoma and normal breast tissue
Expression data from 43 patient-matched breast 
carcinoma and normal breast tissue samples assayed on 
Affymetrix U133A microarrays (GSE15852) was obtained 
from the Gene Expression Omnibus (GEO) [22]. Raw 
data was RMA-normalized, annotated using its associated 
platform annotation file (GPL96-39578) and mean-
centered. Expression levels of the RPL24 probe within the 
patient-matched tumor and normal samples were obtained 
and compared. Significance was assessed using the paired 
t-test. 
Cell culture
SKBR3 human breast cancer cells (American Type 
Culture Collection (ATCC), Rockville, MD) were grown 
in McCoy’s 5A media supplemented with 10% fetal bovine 
serum (FBS) and L-glutamate. 293T cells (American Type 
Culture Collection (ATCC), Rockville, MD) were grown 
in DMEM with 10% FBS and L-glutamate.
shRNA and retroviral infection
Lentiviral vectors containing shRNAs toward 
RPL24, TRCN0000117642/RPL24sh1/target 
sequence CCTGAAGTTAGAAAGGCTCAA and 
TRCN0000117643/RPL24sh2/target sequence 
GTGCATCTCTTGCTGATATAA, and a green fluorescent 
protein control RHS4459/control/target sequence 
TACAACAGCCACAACGTCTAT were purchased 
from Thermo Scientific (formerly Open Biosystems, 
Cincinnati, OH). shRNA expressing lentiviruses were 
produced as previously described [23-25]. Briefly, 293T 
cells were transfected with lentiviral vectors along with 
packaging vectors. One day later, media was changed to 
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Optimem (Life Technologies, Grand Island, NY) and the 
virus was collected for two days and concentrated it as 
outlined previously [26, 27]. SKBR3 cells were infected 
in the presence of 6 µg/ml polybrene with a multiplicity 
of infection of ~2. One day after infection media was 
changed to regular growth media in the case of transient 
infections or growth media with 0.5 µg/ml puromycin in 
the case of stable transfections.
siRNA transfection
The following siRNAs were purchased from 
(Thermo Scientific-Dharmacon, Chicago, IL): HDAC6-
targeting smart pool (L-003499-00) and non-targeting 
control pool (D-001810-10-05). Lipofectamine 2000 
(Life Technologies) was used to transfect SKBR3 cells 
per manufacturer’s protocol. Cells were analyzed 72 hours 
after transfection.
Viability assay
Cells infected with different shRNA-expressing 
lentiviruses were plated in 96-well plates at a density of 
5,000 cells per well. Three hours after plating (T0), a base 
line viability reading was taken using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega, Madison, 
WI). Four days later (T4) another reading was taken 
using the same assay. For each treatment, each of three 
T4 data points was divided by the average of all three T0 
data points for that treatment. The data from the RPL24 
shRNA-treated cells was then normalized to that from the 
control cells. Data is represented by the mean and standard 
deviation of triplicates. 
Cell lysis and western blotting
Cells were lysed in RIPA buffer (10 mM Tris-HCL 
(pH 8.0), 1mM EDTA, 0.5 mM EGTA, 1% triton X-100, 
0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 20 
mM NaF, Complete EDTA-free protease inhibitor tablets 
(Roche Diagnostics Corp., Basel, Switzerland) and the 
phosphatase inhibitor cocktail PhosSTOP (Roche)), the 
latter two as indicated by the manufacturer’s protocol. 
Equal amounts of protein were diluted in 2X sample 
buffer. Immunoblots on PVDF (Polyvinyldene Fluoride) 
membranes were blocked with nonfat milk in tris-buffered 
saline with 0.05% tween-20 (TBST). The following 
antibodies were incubated with membranes in 5% nonfat 
milk in TBST: RPL24 (Proteintech, Chicago, IL), Cyclin 
D1, Rack1, RPL4 (Santa Cruz Biotechnology, Santa 
Cruz, CA), NBS1, GAPDH (EMD Millipore Corporation, 
Chicago, IL), Survivin, β-tubulin, acetyl-lysine, eIF6, 
acetyl-H2B, H2B, (Cell Signaling Technology, Boston, 
MA), acetyl-tubulin, tubulin (Sigma Aldrich (St. Louis, 
MO)). Densitometry was performed using ImageJ 
software. 
Isolation of ribosomes
Cells, plated at ~90% confluency, were treated as 
indicated. After treatment, cells were treated with 50 µg/
ml cycloheximide for 15 minutes. Cells were lysed with 
a buffer containing 10 mM HEPES, 10 mM KCl, 75 mM 
NaCl, 10 mM MgCl2, 0.35% NP40, pH 7.9 supplemented 
with Complete EDTA-free protease inhibitor tablets, 
PhosSTOP phosphatase inhibitor tablets (Roche) per 
manufacturer’s instructions, 50 µg/ml cycloheximide, 
SUPERase RNase inhibitors (Life Technologies) per 
manufacturer’s instructions, 15 µM TSA, and 5 mM 
nicotinimide to inhibit HDACs. Supernatants were 
collected as cytoplasmic preparations. Where indicated, 
pellets containing nuclei were resuspended in RIPA buffer 
(described above). The suspension was spun at 13,000 
rpm for 5 min and supernatants were collected as nuclear 
preparations. 
Ribosomes were subsequently isolated from 
cytoplasmic preparations as described previously [28]. 
Briefly, lysates were layered on top of a 12% and 33% 
discontinuous sucrose gradient and spun at 38,000 rpm for 
2 h. The resulting polysome pellet was then resuspended, 
stripped of RNA with acetic acid, and then pelleted with 
acetone. The pellet was then resuspended in 8 M urea, 2% 
CHAPS, and 25 mM dithiothreitol (DTT).
Polysome profiles to separate the 40S, 60S, 80S and 
polysomes were carried out by layering cell lysates over 
a continuous 10-50% sucrose gradient and spun at 38,000 
rpm for 2 h as previously described [29, 30]. Fractions 
were collected using a Retriever 500 fraction collector 
with a UV (UA6) detector (ISCO Teledyne (Lincoln, 
Nebraska)).
Visualization of crystallography data
Pymol software (Schrodinger, Mannheim, Germany) 
was used to visualize RPL24 and eIF6 on previously 
published crystallography data of the Tetrahymena 
thermophilia 60S ribosomal subunit (human gene names 
used) bound to eIF6 [13]. 
Drugs
TSA was obtained from Sigma Aldrich, Entinostat 
from Syndax (Walthan, MA) and Tubacin (Caymen 
Chemicals, Ann Arbor, MI). ACY-775 was obtained from 
Acetylon Pharmaceuticals (Boston, MA). 
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Mass spectrometry 
To prepare polysome samples for mass spectrometry, 
cells were treated with HDACi and polysome pellets 
were prepared using a discontinuous sucrose gradient as 
described above. Protein concentration was determined 
using the Pierce™ BCA Protein Assay Kit (Thermo 
Scientific) and equal amount of protein were trypsin 
digested. Acetyl-lysine immunoprecipitations were carried 
on resultant peptides out using an antibody from Cell 
Signaling Technology. Acetyl-proteins were then eluted, 
extracted, and desalted. 
To determine the acetylation status of 60S subunit 
proteins, cells were treated with HDACi and polysome 
profiles were performed as described above. The four 
fractions representing the 60S subunit were identified, 
via western blots, for the absence of Rack1 (40S marker) 
and the presence of RPL24 (60S marker). Those 60S 
fractions were then TSA precipitated and reconstituted in 
2% SDS. 60S samples (normalized by protein loading) 
were resolved using 4-12% Bis-Tris gels and stained with 
Imperial Protein Stain (Thermo). Gel bands were excised, 
diced into small pieces, destained, reduced with 10 mM 
dithiothreitol, and alkylated with 5 mM iodoacetamide. In-
gel trypsin digestion was performed using a 1:20 enzyme 
to protein ratio for 16 h at 37oC. Resultant peptides were 
extracted and desalted.
Three biological replicates of polysome or 60S 
samples were then analyzed by LC-MS/MS using a 
quadrupole time-of-flight (QqTOF)TripleTOF 5600 mass 
spectrometer (AB SCIEX, Dublin, CA) coupled to an 
Eksigent (Dublin, CA) nanoLC Ultra, 2D plus. Briefly, 
the resulting peptides were chromatographically separated 
on a C-18 reversed-phase analytical column (75 µm 
I.D.) connected to the TripleTOF 5600 operating in data 
dependent mode (1 MS1 survey scan followed by 30 MS/
MS scans per 1.8 second acquisition cycle) [31]. Mascot 
v2.3.02 and ProteinPilot v4.5 data base searches were 
employed for peptide identification (Table S1, Table S2) 
using a false discovery rate analysis (FDR) of 0.01. For 
MS/MS spectral data of acetylated peptides see Figures 
S3 and S4. Moreover, more detailed interactive viewing 
of spectral libraries is available at the Panorama webserver 
(University of Washington, Seattle), at ‘https://daily.
panoramaweb.org/labkey/project/Gibson/Polysomes_
Benz2/begin.view?’.
Quantitative data analysis of acetyl-lysine peptides 
was performed by integration of selected molecular ion 
intensities using Skyline MS1 Filtering as previously 
described [31]. The average signal intensity, as 
determined by the area under the curve (AUC) of the LC 
chromatogram, of the replicate biological samples was 
calculated. The amount of acetylated peptide normalized 
to total protein loaded onto the gel for each condition was 
determined and the fold induction upon TSA treatment 
was then calculated.
CONCLUSIONS
This is the first study implicating a role for RPL24 
expression in human breast tumors and in regulating 
protein translation necessary for breast tumorigenesis. 
We demonstrate that RPL24 depletion decreases the level 
of proteins synthesized by cap-dependent translation 
essential for cancer cell growth, survival and genome 
repair, without altering the synthesis of housekeeping 
proteins. Polysome profiling indicates that this partial 
translation defect might be related to the control of eIF6 
release from the 60S subunit, inhibiting assembly of 80S 
ribosomes and polysomes. Furthermore, we show that 
HDACi and more specifically, inhibition of HDAC6, 
rapidly induces acetylation of multiple ribosomal proteins, 
and that RPL24 acetylation at K27 is associated with 
impairment in ribosome assembly similarly induced by 
RPL24 depletion. Therefore, our findings point toward 
the existence of an endogenous, HDAC6- and protein 
deacetylation-dependent polysome assembly mechanism 
that can regulate oncogenic growth and potentially serve 
as a novel cancer therapeutic target.
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